Under this arrangement, Quintiles, through its corporate ventures group, PharmaBio Development, will provide ArgoMed with a convertible line of credit to establish a sales force to launch and promote the Thermoflex System in the United States. The arrangement also calls for Innovex, Quintiles' commercialization unit, to deploy the sales force in regions designated by ArgoMed. In addition, PharmaBio has agreed to make an equity investment in ArgoMed.

"This alliance with ArgoMed is another example of how our corporate ventures group delivers business solutions where strategic investments with innovative partners can help create new and significant treatments for patients," said Quintiles Transnational Chairman Dennis Gillings, Ph.D. "At the same time, the expertise of Innovex, our commercialization unit, can help maximize the impact of this important new device. This agreement adds to the momentum that Innovex has created in servicing the medical device industry."

Richard B. Klein, president and chief executive officer, ArgoMed Inc., said: "This alliance allows us to use the considerable resources of Innovex, the premier commercialization resource, in order to help make a minimally invasive procedure more widely available to patients in the United States."

ArgoMed has obtained clearance from the U.S. Food and Drug Administration to market the Thermoflex System in the United States for the treatment of BPH. Currently, Medicare reimbursement for use of the Thermoflex System to treat BPH is available in state programs covering more than 50 percent of the urologists in the U.S., and ArgoMed is working toward receiving approvals in the remaining states.

About Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland that affects half of all men age 50 and over and is associated with painful and difficult urination. Current treatments for BPH include drug therapies, surgery and several relatively new alternative therapies, including procedures that use radio frequency, lasers, microwaves or other methods to relieve the symptoms of BPH.

About ArgoMed
ArgoMed Inc. was founded in Israel during the early 1990s with the mission of developing a system for water-induced thermotherapy. The company filed its first patent application in 1992 and began development of the Thermoflex® System for the treatment of BPH. Based near Research Triangle Park, North Carolina, ArgoMed also has offices in Germany and Israel.

About Quintiles Transnational, PharmaBio and Innovex
Quintiles Transnational is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles employs a global workforce of 18,000 in 39 countries. Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information visit the company's web site at www.quintiles.com.

PharmaBio Development is the corporate ventures group of Quintiles Transnational Corp. that is dedicated to innovative partnering solutions for pharmaceutical and biotech companies.

Innovex, the commercialization unit of Quintiles Transnational Corp., is the world's leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical and biotech products. Across more than 30 therapeutic categories, Innovex has created 72 contract sales forces, with more than 10,000 representatives to launch 19 new products over the last five years.

Information in this press release contains "forward-looking statements" about Quintiles. These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risk that the market for our products and services will not grow as we expect, the risk that our PharmaBio transactions will not generate revenues or profit at the rate or levels we anticipate, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles Transnational Corp.'s recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs. Statements in this release regarding ArgoMed, Thermoflex™ and BPH have been made by ArgoMed and not Quintiles.